Migraine sufferers now have a new tool in their arsenal to fight the debilitating headaches with federal approval of Allergan’s first oral medication proven to ease migraine symptoms within two hours — even after they’ve started.
The Food and Drug Administration approved Ubrelvy, the company’s ubrogepant treatment, on Monday. The oral medication is aimed at treating migraines in patients who are unresponsive to common migraine treatments, such as triptans, or are at risk of cardiovascular disorders. Allergan, which anticipated a December approval by the FDA, said Ubrelvy will be available for sale in the U.S. in the first quarter.
